DBV Technologies S.A. (DBVT)

Market Cap	1.19B +1,131.1%
Revenue (ttm)	5.64M +35.8%
Net Income	-146.95M
EPS	-1.05
Shares Out	235.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,791
Open	21.15
Previous Close	20.45
Day's Range	20.69 - 21.77
52-Week Range	6.69 - 26.19
Beta	-0.20
Analysts	Buy
Price Target	32.04 (+48.95%)
Earnings Date	Apr 29, 2026

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT
• Website: https://www.dbv-technologies.com

Financial Performance

In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price target is $32.04, which is an increase of 48.95% from the latest price.

Price Target

$32.04

(48.95% upside)

Analyst Consensus: Buy